HONG KONG--(Marketwire - Jun 8, 2012) - This morning, [ www.MarketFoundations.com ] announced new reports highlighting Fairchild Semiconductor International (NYSE: [ FCS ]) and Spectrum Pharmaceuticals, Inc. (NASDAQ: [ SPPI ]). Free research downloads are available at [ www.MarketFoundations.com/index.php?coa=FCS&cob=SPPI ].

With markets in correction mode, investors are looking to quantify an accurate model, weighing positives and negatives of the months ahead. Upcoming negative pressures include China's slowdown, the European recession, the end of the Fed's Operation Twist stimulus program, continued geopolitical risks, election uncertainty, and potential 2013 budget bombshell of tax hikes and spending cuts. Meanwhile, positive offsets are driven by central banks (particularly China) cutting rather than hiking rates, deceleration in fuel and food prices, increase in consumer sentiment and resulting retail sales, signs of improvement in housing sales and new strength in auto production schedules.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Market Foundations is releasing new coverage on Fairchild Semiconductor International for its current position within the technology industry. Fairchild Semiconductor International, Inc. (Fairchild) focuses on developing, manufacturing and selling power analog, power discrete and certain non-power semiconductor solutions to a range of end market customers. The Company is a supplier of power analog products, power discrete products and energy-efficient solutions, according to iSuppli. The full research report on Fairchild Semiconductor International (NYSE: [ FCS ]) is available here: [ www.MarketFoundations.com/index.php?coa=FCS ].

Market Foundations has released research on Spectrum Pharmaceuticals, Inc. for its changing role within the healthcare industry. Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with integrated commercial and drug development operations with a focus in hematology and oncology. In the United States, the Company markets two oncology drugs, ZEVALIN and FUSILEV and have two drugs, apaziquone and belinostat, in late stage development along with a pipeline of drug candidates. The full research report on Spectrum Pharmaceuticals, Inc. (NASDAQ: [ SPPI ]) is available here: [ www.MarketFoundations.com/index.php?cob=SPPI ].

About Market Foundations
By providing members with financial information services, we provide the foundation investors need to build investing intelligence. The difference between consistently making good investments or bad investments is nothing more than the right information at the right time.